Michael N. Dudley

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G. Wunderink, Evangelos J. Giamarellos‐Bourboulis, Galia Rahav et al. · Infectious Diseases and Therapy · 2018 · 442 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Scott J. Hecker, K. Raja Reddy, Maxim Totrov et al. · Journal of Medicinal Chemistry · 2015 · 405 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio et al. · Antimicrobial Agents and Chemotherapy · 2017 · 347 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

Roger L. Nation, Jian Li, Otto Cars et al. · The Lancet Infectious Diseases · 2014 · 343 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +15

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis et al. · JAMA · 2018 · 306 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17